ITM Isotopen Technologien München SE

ITM Isotopen Technologien München SE is a privately held biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment. ITM has established GMP manu-facturing and a robust global supply network for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.


ITM at a glance:

Field of Activity
Precision Medicine, Precision Oncology, Targeted Radionuclide Therapy / PRRT

1) Development of targeted radiopharmaceuticals for cancer treatment
2) Therapeutic & diagnostic radioisotopes
3) Equipment for Radiolabeling & Quality Control: iQS-Theranostics Synthesizer, iQS® Ga-68 Fluidic Labeling ­Module, Consumables (Reagent Sets, Cassettes), Quality Control Solution (radio-HPLC)
4) GMP Radiolabeling Service

Our lead candidate Solucin® (n.c.a. 177Lu-Edotreotide) is currently under investigation in the phase III clinical trial COMPETE. COMPETE is an international, multi-center phase III clinical trial evaluating the efficacy and safety of n.c.a. 177Lu-Edotreotide (Solucin®) compared to the standard therapy with Everolimus in patients with inoperable, progressive, somatostatin-receptor positive neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NETs).

Unique Selling Point We are developing and producing ready-to-use radiopharmaceuticals as well as medical radioisotopes, such as the highly pure no-carrier-added Lutetium-177. Known as EndolucinBeta®, it is used for the production of radiopharmaceuticals for cancer treatment. Thanks to our global sales network, we supply our products to more than 3360 sites and reach patients worldwide.
Membership in networks/associations

BioM Biotech Cluster Development GmbH, BIO Deutschland e.V., ENETS European Neuroendocrine Tumor Society, INCA International Neuroendocrine Cancer Alliance, The Carcinoid Cancer Foundation, Inc. (Patient Organization)

Date of Incorporation/
Number of Employees



Address Lichtenbergstr. 1
85748 Garching/Munich
Telephone +49 89 329 8986-600
E-Mail info@itm-radiopharma.com
Web Address www.itm-radiopharma.com
Social Media LinkedIn Twitter Facebook